Can-Fite Biopharma Ltd Sponsore (CANF) 3.85 $CANF
Can-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis
PR Newswire - Wed Feb 04, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. The trial has been completed and the final data is ready for analysis. The Company plans to publish top line results by the end of March 2015. Interim results from this Phase II/III trial and final results from the prior Phase II trial for CF101 in psoriasis were both positive.
CANF: 3.85 (+0.05)
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Panel Comments
Marketwired - Tue Feb 03, 8:15AM CST
Streetwise Reports/The Life Sciences Report released notes from the 2015 Small-Cap Biotech Watchlist panel discussion, which occurred at the Biotech Showcase in San Francisco on January 13. The Watchlist companies selected by top sector analysts include Can-Fite BioPharma Ltd. (NYSE MKT: CANF) and Sunesis Pharmaceuticals (NASDAQ: SNSS). The panel focused on companies they believe should see significant gains in 2015.
CANF: 3.85 (+0.05), SNSS: 2.28 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 8:10AM CST
CANF: 3.85 (+0.05), PHG: 28.93 (-0.07), SIMG: 7.25 (-0.01), FCX: 20.29 (+0.82), AKS: 4.87 (+0.39), CAT: 85.13 (+1.60), NBG: 1.61 (+0.18), MSFT: 43.87 (+0.78)
Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
PR Newswire - Tue Jan 27, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported it has received positive data regarding its CF602 drug candidate in preclinical studies conducted by a third party.
CANF: 3.85 (+0.05)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
Cosentyx cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:11PM CST
CANF: 3.85 (+0.05), JNJ: 99.62 (+1.18), IDRA: 4.10 (-0.14), DERM: 16.52 (-0.11), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), HSP: 87.35 (unch), CELG: 115.88 (+0.16), NVS: 102.20 (-0.17)
Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
PR Newswire - Tue Jan 06, 6:15AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced its anticipated clinical milestones for calendar 2015.
CANF: 3.85 (+0.05)
Ocular Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/ftqgzh/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aerie Pharmaceuticals - Allergan - Amakem - Asahi Kasei Pharma - Bausch & Lomb - Can-Fite BioPharma - F. Hoffmann-La Roche - Inotek Pharmaceuticals - Kowa Company - Merck & Co - Ocular Therapeutix - Ono Pharmaceutical - Otsuka Holdings - Santen Pharmaceutical - Sylentis For more information visit http://www.researchandmarkets.com/research/ftqgzh/ocular
CANF: 3.85 (+0.05), AGN: 229.49 (+1.87), ITEK: (), MRK: 58.81 (-0.07), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01)
Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
PR Newswire - Tue Dec 30, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. Dr. M. Silverman, Can-Fite Medical Director, and Dr. Lee Simon, a key opinion leader in the field of autoimmune inflammatory diseases, designed the Phase III clinical study.
CANF: 3.85 (+0.05)
Can-Fite Enrols First Patient for a Liver Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:10PM CST
Can-Fite (CANF) announced that it started dosing patients for a phase II study on CF 102.
CANF: 3.85 (+0.05), AMGN: 153.48 (+0.30), AFFX: 11.45 (+0.02)
First patient dosed in Phase 2 trial of Can-Fite's liver cancer drug candidate
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:56AM CST
CANF: 3.85 (+0.05)
Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102
PR Newswire - Mon Dec 22, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CANF: 3.85 (+0.05)
Second Part of the Glaucoma Phase II study has been Approved in a European Country
PR Newswire - Mon Dec 15, 6:02AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc. (OTCQB: OPLI), jointly announced today the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second cohort of the Phase II clinical study in glaucoma. OphthaliX plans to conduct the study in two European countries, Bulgaria and Romania. The approval in Romania is expected shortly.
CANF: 3.85 (+0.05)
Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
PR Newswire - Tue Dec 09, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
CANF: 3.85 (+0.05)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:45AM CST
GLOG: 20.00 (+0.21), MILL: 2.07 (+0.09), LPHI: 0.23 (unch), NEOT: 6.69 (-0.04), BOBE: 56.41 (-0.68), FES: 1.19 (+0.06), REDF: 1.98 (+0.03), NKTR: 13.54 (-0.14), PRTO: 10.45 (unch), CANF: 3.85 (+0.05), CALI: 1.35 (+0.06), TRT: 2.85 (unch), SQNM: 3.62 (unch), CARB: 14.96 (+0.07), SEED: 1.38 (-0.02), BLFS: 2.14 (+0.06), DGLY: 11.50 (-0.40), TCCO: 4.32 (-0.07), ALCO: 45.40 (+1.44), PBYI: 205.26 (+2.75)
Can-Fite reports USD8m at-the-market registered direct offering
M2 - Wed Dec 03, 7:07AM CST
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) said on Tuesday that it will sell an aggregate of USD8m of American Depositary Shares (ADSs) in an at-the-market registered direct offering to investors.
CANF: 3.85 (+0.05)
Can-Fite Announces $8 Million At-The-Market Registered Direct Offering
PR Newswire - Tue Dec 02, 4:49PM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA),a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $8 million of American Depositary Shares (ADSs) in an at-the-market registered direct offering. For each ADS purchased, investors will receive one-half of an unregistered warrant to purchase an ADS at an exercise price of $4.45 per ADS, which are exercisable immediately and expire five years from the date of issuance.
CANF: 3.85 (+0.05)
Can-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis
PR Newswire - Wed Feb 04, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. The trial has been completed and the final data is ready for analysis. The Company plans to publish top line results by the end of March 2015. Interim results from this Phase II/III trial and final results from the prior Phase II trial for CF101 in psoriasis were both positive.
CANF: 3.85 (+0.05)
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Panel Comments
Marketwired - Tue Feb 03, 8:15AM CST
Streetwise Reports/The Life Sciences Report released notes from the 2015 Small-Cap Biotech Watchlist panel discussion, which occurred at the Biotech Showcase in San Francisco on January 13. The Watchlist companies selected by top sector analysts include Can-Fite BioPharma Ltd. (NYSE MKT: CANF) and Sunesis Pharmaceuticals (NASDAQ: SNSS). The panel focused on companies they believe should see significant gains in 2015.
CANF: 3.85 (+0.05), SNSS: 2.28 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 8:10AM CST
CANF: 3.85 (+0.05), PHG: 28.93 (-0.07), SIMG: 7.25 (-0.01), FCX: 20.29 (+0.82), AKS: 4.87 (+0.39), CAT: 85.13 (+1.60), NBG: 1.61 (+0.18), MSFT: 43.87 (+0.78)
Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
PR Newswire - Tue Jan 27, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported it has received positive data regarding its CF602 drug candidate in preclinical studies conducted by a third party.
CANF: 3.85 (+0.05)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
Cosentyx cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:11PM CST
CANF: 3.85 (+0.05), JNJ: 99.62 (+1.18), IDRA: 4.10 (-0.14), DERM: 16.52 (-0.11), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), HSP: 87.35 (unch), CELG: 115.88 (+0.16), NVS: 102.20 (-0.17)
Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
PR Newswire - Tue Jan 06, 6:15AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced its anticipated clinical milestones for calendar 2015.
CANF: 3.85 (+0.05)
Ocular Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/ftqgzh/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aerie Pharmaceuticals - Allergan - Amakem - Asahi Kasei Pharma - Bausch & Lomb - Can-Fite BioPharma - F. Hoffmann-La Roche - Inotek Pharmaceuticals - Kowa Company - Merck & Co - Ocular Therapeutix - Ono Pharmaceutical - Otsuka Holdings - Santen Pharmaceutical - Sylentis For more information visit http://www.researchandmarkets.com/research/ftqgzh/ocular
CANF: 3.85 (+0.05), AGN: 229.49 (+1.87), ITEK: (), MRK: 58.81 (-0.07), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01)
Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
PR Newswire - Tue Dec 30, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. Dr. M. Silverman, Can-Fite Medical Director, and Dr. Lee Simon, a key opinion leader in the field of autoimmune inflammatory diseases, designed the Phase III clinical study.
CANF: 3.85 (+0.05)
Can-Fite Enrols First Patient for a Liver Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:10PM CST
Can-Fite (CANF) announced that it started dosing patients for a phase II study on CF 102.
CANF: 3.85 (+0.05), AMGN: 153.48 (+0.30), AFFX: 11.45 (+0.02)
First patient dosed in Phase 2 trial of Can-Fite's liver cancer drug candidate
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:56AM CST
CANF: 3.85 (+0.05)
Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102
PR Newswire - Mon Dec 22, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CANF: 3.85 (+0.05)
Second Part of the Glaucoma Phase II study has been Approved in a European Country
PR Newswire - Mon Dec 15, 6:02AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc. (OTCQB: OPLI), jointly announced today the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second cohort of the Phase II clinical study in glaucoma. OphthaliX plans to conduct the study in two European countries, Bulgaria and Romania. The approval in Romania is expected shortly.
CANF: 3.85 (+0.05)
Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
PR Newswire - Tue Dec 09, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
CANF: 3.85 (+0.05)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:45AM CST
GLOG: 20.00 (+0.21), MILL: 2.07 (+0.09), LPHI: 0.23 (unch), NEOT: 6.69 (-0.04), BOBE: 56.41 (-0.68), FES: 1.19 (+0.06), REDF: 1.98 (+0.03), NKTR: 13.54 (-0.14), PRTO: 10.45 (unch), CANF: 3.85 (+0.05), CALI: 1.35 (+0.06), TRT: 2.85 (unch), SQNM: 3.62 (unch), CARB: 14.96 (+0.07), SEED: 1.38 (-0.02), BLFS: 2.14 (+0.06), DGLY: 11.50 (-0.40), TCCO: 4.32 (-0.07), ALCO: 45.40 (+1.44), PBYI: 205.26 (+2.75)
Can-Fite reports USD8m at-the-market registered direct offering
M2 - Wed Dec 03, 7:07AM CST
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) said on Tuesday that it will sell an aggregate of USD8m of American Depositary Shares (ADSs) in an at-the-market registered direct offering to investors.
CANF: 3.85 (+0.05)
Can-Fite Announces $8 Million At-The-Market Registered Direct Offering
PR Newswire - Tue Dec 02, 4:49PM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA),a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $8 million of American Depositary Shares (ADSs) in an at-the-market registered direct offering. For each ADS purchased, investors will receive one-half of an unregistered warrant to purchase an ADS at an exercise price of $4.45 per ADS, which are exercisable immediately and expire five years from the date of issuance.
CANF: 3.85 (+0.05)
